Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Dec;55(11):1550-7.
doi: 10.1093/cid/cis752. Epub 2012 Aug 31.

Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients

Affiliations

Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients

Greer A Burkholder et al. Clin Infect Dis. 2012 Dec.

Abstract

Background: Individuals infected with human immunodeficiency virus (HIV) are at increased risk for cardiovascular disease (CVD) events compared with uninfected persons. However, little is known about HIV provider practices regarding aspirin (ASA) for primary prevention of CVD.

Methods: A cross-sectional study was conducted among patients attending the University of Alabama at Birmingham 1917 HIV Clinic during 2010 to determine the proportion receiving ASA for primary prevention of CVD and identify factors associated with ASA prescription. Ten-year risk for CVD events was calculated for men aged 45-79 and women aged 55-79. The 2009 US Preventive Services Task Force (USPSTF) guidelines were used to determine those qualifying for primary CVD prevention.

Results: Among 397 patients who qualified to receive ASA (mean age, 52.2 years, 94% male, 36% African American), only 66 (17%) were prescribed ASA. In multivariable logistic regression analysis, diabetes mellitus (odds ratio [OR], 2.60; 95% confidence interval [CI], 1.28-5.27), hyperlipidemia (OR, 3.42; 95% CI, 1.55-7.56), and current smoking (OR, 1.87; 95% CI, 1.03-3.41) were significantly associated with ASA prescription. Odds of ASA prescription more than doubled for each additional CVD-related comorbidity present among hypertension, diabetes, hyperlipidemia, and smoking (OR, 2.13, 95% CI, 1.51-2.99).

Conclusions: In this HIV-infected cohort, fewer than 1 in 5 patients in need received ASA for primary CVD prevention. Escalating likelihood of ASA prescription with increasing CVD-related comorbidity count suggests that providers may be influenced more by co-occurrence of these diagnoses than by USPSTF guidelines. In the absence of HIV-specific guidelines, interventions to improve HIV provider awareness of and adherence to existing general population guidelines on CVD risk reduction are needed.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flow diagram of participant selection of human immunodeficiency virus (HIV)–infected patients qualifying for primary prevention of cardiovascular disease events with aspirin at the University of Alabama at Birmingham 1917 HIV Clinic. Abbreviations: ASA, aspirin; CVD, cardiovascular disease; FRS, Framingham Risk Score; USPSTF, United States Preventive Services Task Force.
Figure 2.
Figure 2.
Increasing odds of aspirin (ASA) prescription with increasing cardiovascular disease (CVD)–related comorbidity counta in human immunodeficiency virus (HIV)–infected patients (N = 397) at the University of Alabama at Birmingham 1917 HIV Clinic meeting 2009 United States Preventive Services Task Force criteria [16] for ASA for primary prevention of CVD events. Abbreviations: ASA, aspirin; CI, confidence interval; CVD, cardiovascular disease; OR, odds ratio. aIncludes diabetes mellitus, hypertension, hyperlipidemia, and current smoking.

Similar articles

Cited by

References

    1. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22–9. - PubMed
    1. Effros RB, Fletcher CV, Gebo K, et al. Workshop on HIV infection and aging: what is known and further research directions. Clin Infect Dis. 2008;47:542–53. - PMC - PubMed
    1. Marin B, Thiébault R, Buchar HC, et al. Non-AIDS defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS. 2009;23:1743–53. - PMC - PubMed
    1. Neuhaus J, Angus B, Kowalska JD, et al. Risk of all-cause mortality associated with non-fatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS. 2010;24:697–706. - PMC - PubMed
    1. The Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010;50:1387–96. - PMC - PubMed

Publication types